Video
Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.
Robert J. Motzer, MD, Kidney Cancer section head, genitourinary oncology service and Jack and Dorothy Byrne chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, discusses the importance of assessing health-related quality of life (HRQOL) in renal cell carcinoma (RCC).
HRQOL assessments provide insight into how patients perceive the regimen’s tolerability and how they feel about being on the regimen overall, Motzer explains. HRQOL assessments yield important information for data interpretation and treatment decisions, Motzer adds.
During the 2021 ASCO Annual Meeting, findings from a HRQOL analysis from the phase 3 CLEAR trial (NCT02811861) were presented. The results demonstrated that patients with advanced RCC treated with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) had similar or better symptoms and HRQOL compared with patients treated with sunitinib (Sutent). Historically, sunitinib was a standard of care option for patients with advanced RCC, so these findings confirmed that the improved efficacy demonstrated with first-line lenvatinib plus pembrolizumab vs sunitinib in the CLEAR trial does not comprise tolerability, Motzer concludes.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
2 Commerce Drive
Cranbury, NJ 08512